Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy - Archive ouverte HAL Access content directly
Journal Articles European Journal of Cancer Year : 2021

Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy

Clarice Groeneveld
Jacqueline Fontugne
  • Function : Author
Luc Cabel
  • Function : Author
Yves Allory
Aurélien de Reyniès
  • Function : Author
Not file

Dates and versions

hal-03453779 , version 1 (28-11-2021)

Identifiers

Cite

Clarice Groeneveld, Jacqueline Fontugne, Luc Cabel, Isabelle Bernard-Pierrot, François Radvanyi, et al.. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. European Journal of Cancer, 2021, 148, pp.181-189. ⟨10.1016/j.ejca.2021.01.036⟩. ⟨hal-03453779⟩

Collections

CNRS FNCLCC CURIE
12 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More